Another failed midstage asset for Acceleron, another pipeline test dumped

Acceleron has chalked up another phase 2 flop as its pipeline thins a little more.

The biotech, a former Fierce 15 winner, has had a roller coaster few years. The highs have predominately come from its Celgene/Bristol-Myers Squibb-partnered blood cancer drug luspatercept, a first-in-class erythroid maturation agent that could gain FDA approvals in December and April, respectively, after getting a priority review for its beta-thalassemia label and a standard review for its drug in myelodysplastic syndromes-associated anemia.